drugset / Trial / NCT03836157
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
NaSingle-groupOpen-labelTreatment
Summary
IMGN853 is designed to inhibit cell division and cell growth of folate receptor 1 (FRα)-expressing tumor cells. The purpose of this study is to test the safety of IMGN853 and bevacizumab and see what effects (good and bad) that this combination treatment has on subjects with recurrent endometrial cancer.
Timeline
- Start
- 2019-05-31
- Primary completion
- 2021-11-30
- Completion
- 2022-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Mirvetuximab Soravtansine | Other / unclassified | 6 mg/kg | Intravenous |